Filtered By:
Drug: Tamoxifen
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 2054 results found since Jan 2013.
Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway
Am J Physiol Cell Physiol. 2023 Aug 14. doi: 10.1152/ajpcell.00199.2023. Online ahead of print.ABSTRACTBreast cancer is the leading cause of cancer deaths for women worldwide. Endocrine therapies represent the cornerstone for hormone-dependent breast cancer treatment. However, in many cases, endocrine resistance is induced with poor prognosis for patients. In the current study, we have developed MCF-7 cell lines resistant to Fulvestrant (MCF-7Fulv) and Tamoxifen (MCF-7Tam) aiming at investigating mechanisms underlying resistance. Both resistant cell lines exerted lower proliferation capacity in 2D cultures but retain ERα ...
Source: Am J Physiol Cell Ph... - August 14, 2023 Category: Cytology Authors: Konstantinos E Siatis Efstathia Giannopoulou Dimitra Manou Panagiotis Sarantis Michalis V Karamouzis Sofia Raftopoulou Konstantinos Fasseas Fatimah Mohammed Alzahrani Haralabos P Kalofonos Achilleas D Theocharis Source Type: research
Circulating miR-221/222 expression as microRNA biomarker predicting tamoxifen treatment outcome: a case-control study
CONCLUSION: The use of circulating miR-221/222 expression can predict relapse as well as resistance to tamoxifen treatment in BC patients, and their testing is recommended for luminal subtype BC patients who will undergo tamoxifen therapy to determine their risk of tamoxifen resistance early, increasing treatment effectiveness.PMID:37554919 | PMC:PMC10406100 | DOI:10.1097/MS9.0000000000001061
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Ilhamjaya Patellongi Alfiah Amiruddin Muhammad N Massi Andi A Islam Muhammad Y Pratama Noorwati Sutandyo Nani H M Latar Muhammad Faruk Source Type: research
Effect of Tamoxifen on Proteome Expression during < em > In Vitro < /em > Myogenesis in Murine Skeletal Muscle C < sub > 2 < /sub > C < sub > 12 < /sub > Cells
We report a tandem mass-tag approach to TMX-treated myogenesis in C2C12 cells, a well-characterized model of in vitro murine skeletal muscle differentiation. A longitudinal analysis of >10,000 proteins identified in untreated C2C12 myogenesis revealed a novel subset of 1,062 myogenically regulated proteins. These proteins clustered into five distinct longitudinal expression trends which significantly overlap those obtained in similar analyses performed in human myocytes. We document a specific functional enrichment for adiponectin-signaling unique to TMX-treated myogenesis, as well as a subset of 198 proteins that are d...
Source: Cell Research - August 8, 2023 Category: Cytology Authors: Emily A Morris Ahlenne Abreu Stylianos P Scordilis Source Type: research
Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study
CONCLUSION: Oral MCT was found to be an effective and well-tolerated regime with good symptomatic control and low-moderate toxicity profile in patients with relapsed and metastatic ovarian cancer. However, 22% of patients showed grade-III/IV thrombocytopenia.PMID:37530237 | DOI:10.4103/ijc.IJC_143_20
Source: Cancer Control - August 2, 2023 Category: Cancer & Oncology Authors: Kamlesh K Harsh Shankar L Jakhar Guncha Maheshwari Rajkumar Nirban Pramila Kumari Surender K Beniwal Neeti Sharma Harvindra S Kumar Source Type: research
HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
CONCLUSION: Tamoxifen for ER-/PR-positive NETs patients is safe but offers modest antitumor effects.TRIAL REGISTRY NAME: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET).URL: https://clinicaltrials.gov/ct2/show/NCT03870399?term=03870399&draw=2&rank=1.REGISTRATION NUMBER: NCT03870399.PMID:37529158 | PMC:PMC10387775 | DOI:10.1177/17588359231186041
Source: Cancer Control - August 2, 2023 Category: Cancer & Oncology Authors: Milton J Barros Jonathan Strosberg Taymeyah Al-Toubah Victor Hugo F de Jesus Lais Durant Celso A Mello Tiago C Felismino Louise De Brot Rodrigo G Taboada Mauro D Donadio Rachel P Riechelmann Source Type: research
Developmental origin of the mammalian premaxilla
Dev Biol. 2023 Jul 29:S0012-1606(23)00137-9. doi: 10.1016/j.ydbio.2023.07.005. Online ahead of print.ABSTRACTThe evolution of jaws has played a major role in the success of vertebrate expansion into a wide variety of ecological niches. A fundamental, yet unresolved, question in craniofacial biology is about the origin of the premaxilla, the most distal bone present in the upper jaw of all amniotes. Recent reports have suggested that the mammalian premaxilla is derived from embryonic maxillary prominences rather than the frontonasal ectomesenchyme as previously shown in studies of chicken embryos. However, whether mammalian...
Source: Developmental Biology - July 31, 2023 Category: Biology Authors: PaulP R Iyyanar Chuanqi Qin Nirpesh Adhikari Han Liu Yueh-Chiang Hu Rulang Jiang Yu Lan Source Type: research
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
CONCLUSION: Three more years of tamoxifen therapy reduced the risk of breast cancer mortality. The difference was established during the first 15 years after randomization. Moreover, the incidence of contralateral breast cancer gradually decreased for 30 years. The incidence of lung cancer was reduced in the five-year group. In contrast the incidence of endometrial cancer was increased.PMID:37517154 | DOI:10.1016/j.breast.2023.07.010
Source: Breast - July 30, 2023 Category: Cancer & Oncology Authors: Anna Nordenskj öld Helena Fohlin Johan Rosell Nils-Olof Bengtsson Tommy Fornander Thomas Hatschek Henrik Lindman Per Malmstr öm Lisa Ryd én Arne Wallgren Olle St ål Bo Nordenskj öld Source Type: research
